Rua Life Sciences PLC
LSE:RUA
Intrinsic Value
RUA Life Sciences Plc is a holding company, which engages in the commercialization of biomedical polymer technology, components, and medical devices. [ Read More ]
The intrinsic value of one
RUA
stock under the Base Case scenario is
10.59
GBX.
Compared to the current market price of 11.75 GBX,
Rua Life Sciences PLC
is
Overvalued by 10%.
Rua Life Sciences PLC's market capitalization is 7.3m GBX.
RUA stock price is 11.75 GBX.
RUA stock (10.59 GBX) is 10% less than its price (11.75 GBX).
RUA stock price (11.75 GBX) is 42% less than its Relative Value (20.38 GBX). Open Relative Valuation
RUA has upside potential of 117% compared to the average analyst price target.
Open Wall St Estimates
RUA's Revenue has dropped by 8% over the past 12 months.
RUA's Revenue is forecast to grow at a rate of 27% per year over the next 3 years.
RUA has negative Net Debt. This means that the company has more cash and short-term investments (493k GBP) than debt (319k GBP).
RUA's Altman Z-Score is very low and is equal to 1.8.
RUA has negative Operating Income for the last twelve months.
RUA has negative Net Income for the last twelve months.
RUA's ROE (Return on Equity) for the past 12 months is negative and is equal to -41%.
RUA's ROIC (Return on Invested Capital) for the past 12 months is negative and is equal to -47%.
RUA's short-term assets (1m GBP) exceed its short-term liabilties (520k GBP).
RUA has positive Gross Profit for the last twelve months.
RUA has negative Free Cash Flow for the last twelve months.
RUA's D/E (Debt to Equity) is very low and is equal to 0.09.
RUA has negative three-year average ROE (Return on Equity): -35%. The company is not efficient at transforming stockholders' equity into net income.
RUA has negative three-year average ROIC (Return on Invested Capital): -57%. The company is not efficient at using invested capital to generate operating income.
RUA's long-term assets (5m GBP) exceed its long-term liabilties (1m GBP).
Valuation Backtest
Rua Life Sciences PLC
Run backtest to discover the historical profit from buying and selling
RUA
stocks based on their intrinsic value.
Analyze the historical link between intrinsic value and market price to make more informed investment decisions.
Fundamental Analysis
Rua Life Sciences PLC
Balance Sheet Decomposition
Rua Life Sciences PLC
| Current Assets | 1.4m |
| Cash & Short-Term Investments | 493k |
| Receivables | 529k |
| Other Current Assets | 365k |
| Non-Current Assets | 3.4m |
| PP&E | 2.6m |
| Intangibles | 746k |
| Current Liabilities | 520k |
| Accounts Payable | 184k |
| Accrued Liabilities | 146k |
| Other Current Liabilities | 190k |
| Non-Current Liabilities | 500k |
| Long-Term Debt | 319k |
| Other Non-Current Liabilities | 181k |
Earnings Waterfall
Rua Life Sciences PLC
|
Revenue
|
1.9m
GBP
|
|
Cost of Revenue
|
-337k
GBP
|
|
Gross Profit
|
1.5m
GBP
|
|
Operating Expenses
|
-4.1m
GBP
|
|
Operating Income
|
-2.5m
GBP
|
|
Other Expenses
|
660k
GBP
|
|
Net Income
|
-1.9m
GBP
|
Free Cash Flow Analysis
Rua Life Sciences PLC
RUA Profitability Score
Profitability Due Diligence
Rua Life Sciences PLC's profitability score is 25/100. The higher the profitability score, the more profitable the company is.
Score
Rua Life Sciences PLC's profitability score is 25/100. The higher the profitability score, the more profitable the company is.
RUA Solvency Score
Solvency Due Diligence
Rua Life Sciences PLC's solvency score is 66/100. The higher the solvency score, the more solvent the company is.
Score
Rua Life Sciences PLC's solvency score is 66/100. The higher the solvency score, the more solvent the company is.
Wall St
Price Targets
RUA Price Targets Summary
Rua Life Sciences PLC
According to Wall Street analysts, the average 1-year price target for
RUA
is 25.5 GBX
with a low forecast of 25.25 GBX and a high forecast of 26.25 GBX.
Shareholder Return
RUA Price
Rua Life Sciences PLC
| Average Annual Return | 4.06% |
| Standard Deviation of Annual Returns | 57.78% |
| Max Drawdown | -95% |
| Market Capitalization | 7.3m GBX |
| Shares Outstanding | 62 060 300 |
| Percentage of Shares Shorted |
N/A
|
Company Profile
Rua Life Sciences PLC
Country
Industry
Market Cap
Dividend Yield
Description
RUA Life Sciences Plc is a holding company, which engages in the commercialization of biomedical polymer technology, components, and medical devices. The company is headquartered in Ayrshire, Ayrshire and currently employs 32 full-time employees. The firm is a manufacturer of medical devices and licensor of its IP and know-how together with developing medical devices utilizing its polymer IP. The firm operates through four businesses. Its RUA Medical business provides sub-contract manufacturing, assembly, packing and services to the medical device sector from its Class seven and eight cleanroom suites. Its RUA Biomaterials is the depository of the IP and licensing rights to a range of biostable, implantable polymers, including Elast-EonTM and ECSilTM. Its RUA Vascular business is the legal manufacturer and IP holder of the Company’s cardiovascular and soft tissue patches and bore vascular grafts. Its RUA Structural Heart business holds the intellectual property relating to the Company’s synthetic heart valve technology.
Contact
IPO
Employees
Officers
The intrinsic value of one
RUA
stock under the Base Case scenario is
10.59
GBX.
Compared to the current market price of 11.75 GBX,
Rua Life Sciences PLC
is
Overvalued by 10%.
You don't have any saved screeners yet
